Scholars Central

Conference abstractPublished 26 Jun 2017

Polypeptide GalNAc-transferase-13 shows independent prognostic impact in adenocarcinoma lung cancer patients treated with neoadjuvant chemotherapy

Authors: Eduardo Osinaga, Nora Berois, Diego Touya, Carmen Behrens, Rafael Alonso, Maria Florencia Festari, Otto Pritsch, Mario Varangot, Ignacio Wistuba

Institut Pasteur de Montevideo, Uruguay; Servicio de OncologÃ?a ClÃ?nica, Uruguay; University of Texas MD Anderson Cancer Center, USA; Facultad de Medicina, Uruguay

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Lung cancer is currently the leading cause of cancer-related death worldwide, accounting for approximately a third of all cancer diagnoses and related-deaths. Non-small cell lung cancer (NSCLC) represents nearly 80% of lung tumors; the two most common NSCLC histological types are squamous cell carcinoma (SCC) and adenocarcinoma (ADCA). Several diagnosis procedures detecting altered glycosylation have been developed and incorporated as assistant procedures in clinical oncology. The synthesis of mucintype O-glycans is started in a reaction catalyzed by UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferases (GalNAc-Ts). This is a complex family of enzymes of at least 20 members in humans. We previously found that GALNT13, the gene encoding GalNAc-T13 isoenzyme, is a strong predictor of poor clinical outcome in neuroblastoma patients. In the present study, we evaluated GalNAc-T13 expression in human NSCLC. We produced a monoclonal antibody (MAb T13.5) that was used to assess the expression profile of the GalNAc-T13 protein in a well-defined population of 443 surgically resected NSCLC patients with 7 years of follow-up. We found that ADCAs expressed higher levels of the enzyme than SCCs. GalNAc-T13 expression correlated significantly with worse overall survival in ADCA patients treated with neoadjuvant chemotherapy. These data suggest that GalNAc-T13 could be a novel marker associated to chemoresistance in lung adenocarcinomas.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Glycobiology.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Glycobiology
  • SubjectOncology & Cancer
  • SubjectPulmonology & Respiratory
  • BylineArticles whose byline prints “Eduardo Osinaga”
  • BylineArticles whose byline prints “Nora Berois”
  • BylineArticles whose byline prints “Diego Touya”
  • BylineArticles whose byline prints “Carmen Behrens”
  • BylineArticles whose byline prints “Rafael Alonso”
  • BylineArticles whose byline prints “Maria Florencia Festari”
  • BylineArticles whose byline prints “Otto Pritsch”
  • BylineArticles whose byline prints “Mario Varangot”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels